These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3497401)

  • 1. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
    Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5995-9. PubMed ID: 3497401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
    Ho VW; Porrino LJ; Crane AM; Burns RS; Kopin IJ; Sokoloff L
    Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
    Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
    Life Sci; 1987 Apr; 40(17):1657-64. PubMed ID: 3494179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
    Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
    Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW
    Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP.
    Palombo E; Porrino LJ; Bankiewicz KS; Crane AM; Sokoloff L; Kopin IJ
    J Neurosci; 1990 Mar; 10(3):860-9. PubMed ID: 2319306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Brain Res; 1985 Dec; 358(1-2):137-43. PubMed ID: 3878182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates.
    Palombo E; Porrino LJ; Bankiewicz KS; Crane AM; Kopin IJ; Sokoloff L
    Brain Res; 1988 Jun; 453(1-2):227-34. PubMed ID: 3261197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
    Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
    Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
    Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
    Wolters EC; Kebabian JC; Guttman M; Mak E; Pate BD; Calne DB
    Neurosci Lett; 1988 Dec; 95(1-3):257-61. PubMed ID: 3265771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
    Cao X; Liang L; Hadcock JR; Iredale PA; Griffith DA; Menniti FS; Factor S; Greenamyre JT; Papa SM
    J Pharmacol Exp Ther; 2007 Oct; 323(1):318-26. PubMed ID: 17630359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
    Schultz W; Studer A; Jonsson G; Sundström E; Mefford I
    Neurosci Lett; 1985 Aug; 59(2):225-32. PubMed ID: 3877257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.